Cancer treatment just got a potential game-changer! A team of brilliant chemists at The University of Hong Kong (HKU), in collaboration with researchers from Shenzhen Bay Laboratory and Tsinghua University, has made a groundbreaking discovery in the fight against cancer. They've developed a first-of-its-kind chemical inhibitor that could revolutionize how we treat non-small cell lung cancer (NSCLC). But what makes this so special? And how does it work? Let's dive in!
This research, recently published in the prestigious journal Nature Chemical Biology, focuses on the fascinating world of epigenetics – the study of how our genes are controlled. Think of your DNA as a vast library, and genes are individual books within it. Epigenetics is like the librarian, deciding which books are available and which ones are kept on the shelves. These decisions are made through chemical modifications, like tiny switches, that tell our cells which genes to 'turn on' or 'turn off.'
Histone Modifications: The Cellular Switchboard
Inside our cells, DNA is wrapped around proteins called histones, forming a structure called chromatin. Certain chemical modifications on these histones act like genetic switches. One crucial modification is histone acetylation, which acts as an 'on' switch, activating gene expression. This process is controlled by enzymes called histone acetyltransferases (HATs).
The team focused on the ATAC complex, a HAT complex that plays a vital role in activating genes involved in cell growth and DNA replication. In cancers like NSCLC, the ATAC complex goes into overdrive, inappropriately switching on genes that drive tumor growth. The challenge? Finding a way to target the ATAC complex without disrupting other essential cellular functions.
Precision Targeting: A Novel Approach
Previous attempts to target cancer focused on inhibiting GCN5, a key component of the ATAC complex. However, GCN5 is also found in other HAT complexes, which means that targeting it would cause significant side effects. But here's where it gets controversial... Professor Li's team took a different approach. They targeted YEATS2, a protein subunit specific to the ATAC complex. Using structure-guided design, they created LS-170, a highly selective inhibitor of YEATS2. This inhibitor binds to the acetyl-lysine recognition domain of YEATS2, preventing the ATAC complex from attaching to the DNA and activating the cancer-causing genes.
Impressive Results in the Lab
LS-170 showed remarkable results in both NSCLC cell lines and animal models, significantly reducing tumor growth and metastasis.
Figure 1. Tumour suppression in vivo — In animal models, LS-170 treatment significantly reduced tumour volume, demonstrating its strong anti-cancer potential. (Image adapted from the relevant journal.)
This is a huge step forward, and the fact that the YEATS2 gene is often amplified in other solid tumors, including ovarian and pancreatic cancers, suggests that this strategy could be effective in treating a wider range of cancers.
A New Era in Cancer Treatment?
This study is the first chemical approach to precisely decode the function of a specific HAT complex, revealing ATAC's distinct role in maintaining gene expression programs in cancer. It also offers new insights for developing other complex-specific epigenetic drugs for human diseases.
Professor Xiang Li, one of the corresponding authors, stated, "In this work, we didn't just create a potent and highly specific inhibitor that can suppress tumours, we also uncovered a novel strategy to target just one epigenetic complex out of several that share the same enzyme core. This approach opens up exciting possibilities for developing highly selective, complex-specific drugs that could potentially revolutionise treatments for human diseases."
Who Made This Breakthrough?
The research was a collaborative effort led by Professor Xiang David LI (HKU Chemistry), along with Professor Weiping WANG (HKU Pharmacology and Pharmacy), Researcher Xin LI (Shenzhen Bay Laboratory), and Professor Haitao LI (Tsinghua University). The co-first authors included Dr. Sha LIU, Dr. Yin Qiao WU, Dr. Jinzhao LIU, and Dr. Xinyi YAO.
What do you think? Could this be a turning point in cancer treatment? Do you think this targeted approach is the future of medicine? Share your thoughts in the comments below! And this is the part most people miss... For more details, you can read the full journal paper here:
